Financial Performance - The company's operating revenue for 2021 was ¥1,776,317,811.37, representing a 12.29% increase compared to ¥1,581,905,632.48 in 2020[23] - The net profit attributable to shareholders of the listed company decreased by 5.89% to ¥382,286,663.10 in 2021 from ¥406,195,463.57 in 2020[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥370,633,265.99, down 5.50% from ¥392,188,209.82 in the previous year[23] - The net cash flow from operating activities was ¥533,084,549.84, a decrease of 23.8% compared to ¥699,612,782.08 in 2020[23] - The total assets at the end of 2021 were ¥6,603,925,651.78, reflecting a 5.19% increase from ¥6,278,282,683.24 at the end of 2020[23] - The net assets attributable to shareholders of the listed company increased by 5.83% to ¥5,272,250,740.06 at the end of 2021 from ¥4,981,663,905.19 at the end of 2020[23] - Basic earnings per share were 0.34 RMB, down 5.56% from 0.36 RMB in 2020[26] - The weighted average return on equity was 7.39%, a decrease of 0.98 percentage points from 8.37% in 2020[26] Research and Development - Research and development expenses amounted to 267 million RMB, an increase of 28.99%, representing 15.04% of operating revenue[35] - The company obtained 13 invention patents, 3 utility model patents, and received approval for 6 clinical trial permits and 2 new veterinary drug registration certificates[38] - The company’s animal biosafety level 3 laboratory (ABSL-3) has been granted additional licenses for research on various viral diseases, enhancing its research capabilities[38] - The company’s vaccine pipeline focuses on effective antigen screening and breakthroughs in new subunit and mRNA vaccine technologies for African swine fever[38] - The company has established over ten research and development platforms, including pathogen detection, viral vaccine, and recombinant protein platforms, enhancing its vaccine development capabilities[49] - The company is actively involved in the research and development of vaccines for major animal diseases, ensuring compliance with national standards and improving food safety[46] Market and Sales Strategy - The company employs a multi-channel sales strategy, including direct sales to large clients, a distributor network, and government tender procurement, to enhance market penetration[52] - The company has adjusted its marketing strategy in response to competitive pressures, focusing on team coordination and technology to maintain market share in the animal health industry[52] - The company focuses on providing tailored disease prevention solutions to large clients, fostering strategic partnerships and shared resources[52] - The company has maintained its leading market share in foot-and-mouth disease vaccines while increasing its share in non-foot-and-mouth vaccines[64] Corporate Governance - The company held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, particularly minority shareholders[147] - Six board meetings were conducted, with directors actively participating in training to enhance decision-making capabilities[147] - The management team operates under the board's directives, ensuring clear roles and responsibilities within the organization[147] - The company emphasizes the importance of information disclosure and investor relations, maintaining transparency and communication with stakeholders[147] - The total pre-tax remuneration for Chairman Zhang Chongyu during the reporting period was CNY 1.95 million[153] Risk Management - The company has detailed potential risks in the report, which investors are advised to review[8] - The company faces risks related to the resurgence of the African swine fever, which may impact vaccine demand due to uncertainties in the recovery speed of the pig farming industry[144] - The competitive landscape is evolving as the company adapts to a multi-faceted environment driven by R&D, biosecurity, process optimization, quality control, and technical services[144] - The company acknowledges the long R&D cycles and high investment costs associated with veterinary vaccine products, which may lead to uncertainties in meeting market demand[144] Employee Development - The company has implemented a comprehensive training program to enhance the capabilities of mid-to-senior management, focusing on talent development[183] - The company’s management team has extensive experience in the biotechnology and pharmaceutical sectors, enhancing its strategic capabilities[156] - The employee composition includes 422 production staff, 196 sales personnel, 339 technical staff, 47 financial staff, 98 administrative staff, 211 management staff, and 267 others[179] Dividend Policy - The company plans to distribute a cash dividend of ¥1.10 per 10 shares (including tax) to all shareholders[6] - The company’s profit distribution policy emphasizes a minimum cash dividend of 30% of the average distributable profit over the last three years[187] - Cash dividends should constitute at least 80% of the total profit distribution if the company is in a mature stage without major capital expenditure plans[187] - The company’s cash flow must be sufficient to support normal operations and long-term development before implementing cash dividends[188]

Financial Performance - The company's operating revenue for Q3 2021 was ¥497,962,981.50, representing a year-on-year increase of 3.02%[7] - The net profit attributable to shareholders for Q3 2021 was ¥160,678,332.58, reflecting a significant increase of 41.83% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥136,438,700.63, up by 23.43% year-on-year[11] - The basic earnings per share for Q3 2021 was ¥0.14, an increase of 40.00% compared to the same period last year[11] - Net profit for the first three quarters of 2021 was ¥454,201,985.59, compared to ¥349,815,780.97 in the same period of 2020, indicating a growth of 29.8%[39] - The net profit attributable to the parent company's shareholders was CNY 418,621,189.85, an increase from CNY 295,732,932.28, representing a growth of approximately 41.5% year-over-year[41] - The total comprehensive income attributable to the parent company's shareholders reached CNY 418,898,934.30, compared to CNY 295,938,327.05 in the previous year, indicating a year-over-year increase of about 41.5%[44] - Basic and diluted earnings per share were both CNY 0.37, up from CNY 0.26 in the same period last year, reflecting a growth of approximately 42.3%[44] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,555,290,017.34, which is a 4.41% increase from the end of the previous year[11] - The equity attributable to shareholders at the end of the reporting period was ¥5,288,932,827.82, up by 6.17% year-on-year[11] - Total assets as of Q3 2021 amounted to ¥6,555,290,017.34, an increase from ¥6,278,282,683.24 in Q3 2020, representing a growth of 4.4%[35] - Total liabilities decreased to ¥977,639,614.26 in Q3 2021 from ¥1,015,342,820.46 in Q3 2020, a reduction of 3.7%[35] - The company's total current assets amounted to RMB 3,143,308,830.04, a decrease of 1.37% from RMB 3,187,018,741.38 on December 31, 2020[29] - The company's total liabilities as of September 30, 2021, are not explicitly stated but are essential for assessing financial health[29] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥257,770,973.41, showing a decrease of 36.18% compared to the previous year[11] - Cash inflow from operating activities totaled CNY 1,194,933,674.77, slightly up from CNY 1,193,422,788.19, showing a marginal increase of 0.13%[44] - The net cash flow from operating activities was CNY 257,770,973.41, down from CNY 403,880,298.08, indicating a decrease of approximately 36.2% year-over-year[47] - The company reported cash inflow from investment activities of CNY 451,631,093.82, compared to CNY 539,714,796.79 in the previous year, reflecting a decline of about 16.3%[47] - The net cash flow from investment activities was negative at CNY -19,687,162.99, a significant improvement from CNY -450,222,980.92 in the previous year[47] - The total cash and cash equivalents at the end of the period were CNY 1,440,193,503.87, up from CNY 833,261,932.89, representing an increase of approximately 73%[47] - The company received CNY 13,117,786.50 from financing activities, while cash outflow for financing activities was CNY 131,986,784.80, leading to a net cash flow of CNY -118,868,998.30[47] Shareholder Information - The company had a total of 60,708 common shareholders at the end of the reporting period[18] - The largest shareholder, Hong Kong Central Clearing Limited, held 11.43% of the shares, while Inner Mongolia Jinyu Biological Holdings Limited held 10.86%[18] Inventory and Investments - The company's inventory decreased to RMB 320,408,173.56 from RMB 350,661,798.80, a reduction of 8.6%[29] - The company’s long-term equity investments slightly decreased to RMB 263,641,045.75 from RMB 266,722,496.16, a decline of 1.1%[29] - The company’s fixed assets decreased to RMB 1,636,586,113.04 from RMB 1,698,893,578.48, reflecting a decline of 3.7%[29] Research and Development - Research and development expenses increased to ¥96,347,351.37 in Q3 2021, compared to ¥84,962,776.40 in Q3 2020, marking a rise of 13.5%[38] Other Developments - The company plans to raise up to RMB 900 million through a non-public offering of A-shares, with a maximum issuance of 63,157,895 shares at a price of RMB 14.25 per share[25] - The company’s subsidiary has received a new veterinary drug registration certificate for its recombinant vaccines, indicating progress in product development[25]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥840,429,279.75, representing a 34.61% increase compared to ¥624,355,493.78 in the same period last year[20]. - The net profit attributable to shareholders for the first half of 2021 was ¥257,942,857.27, up 41.38% from ¥182,445,680.86 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥251,503,376.55, reflecting a 39.61% increase from ¥180,151,927.28 in the same period last year[20]. - Basic earnings per share for the first half of 2021 were ¥0.23, a 43.75% increase from ¥0.16 in the same period last year[20]. - The weighted average return on net assets increased by 1.19 percentage points to 5.04% from 3.85% in the previous year[20]. - The company achieved operating revenue of 840 million yuan, a year-on-year increase of 34.61%; net profit attributable to shareholders was 258 million yuan, up 41.38% year-on-year[39]. - The company reported a net profit for the first half of 2021 reached CNY 264,861,106, an increase of 39.2% compared to CNY 190,186,198 in the same period of 2020[123]. - The total comprehensive income for the current period amounted to CNY 258,150,823.52, which includes a net profit of CNY 257,942,857.27[144]. Cash Flow and Assets - The net cash flow from operating activities decreased by 24.84% to ¥80,034,359.97 from ¥106,483,123.49 in the previous year[20]. - The total assets at the end of the reporting period were ¥6,347,505,359.72, a 1.10% increase from ¥6,278,282,683.24 at the end of the previous year[20]. - The company's total assets as of June 30, 2021, amounted to RMB 4,649,282,287.29, a slight increase from RMB 4,623,475,524.00 at the end of 2020[117]. - Cash and cash equivalents decreased to RMB 729,472,606.15 as of June 30, 2021, from RMB 840,062,902.98 at the end of 2020, a decline of 13.2%[114]. - The total equity of the company increased to RMB 4,493,832,732.79 as of June 30, 2021, compared to RMB 4,308,367,634.85 at the end of 2020, reflecting a growth of 4.3%[119]. Research and Development - R&D investment reached 84.19 million yuan, accounting for 10.02% of operating revenue, with significant progress in multiple research paths for African swine fever vaccines[39]. - The company has established over ten R&D platforms, including pathogen diagnosis, cell technology, and gene engineering expression platforms, enhancing its research capabilities and industry position[36]. - The company has developed a dedicated R&D team for various vaccines, including African swine fever and brucellosis vaccines, covering multiple vaccine development technologies[36]. - The company reported investment income of CNY 298,143,980.92 for the first half of 2021, significantly higher than CNY 189,002,385.62 in the previous year, marking a growth of 57.8%[125]. Market Position and Strategy - The company focuses on the development of animal vaccines, maintaining a leading market share in foot-and-mouth disease vaccines[26]. - The company is actively promoting the internationalization of its products, with a steady increase in market share in the vaccine procurement sector[26]. - The company operates a "sales-driven production" model, coordinating production and sales plans across departments to optimize resource allocation[32]. - The company has established a joint venture with a Japanese pharmaceutical company to develop and market pet vaccines in China, tapping into the domestic pet health market[33]. Environmental and Social Responsibility - Jin Yu Bao Ling invested CNY 92.34 million in environmental protection measures during the construction of its biotechnology park[71]. - The wastewater treatment plant at Jin Yu Bao Ling has a designed capacity of 1,000 m³/d, utilizing a "pulse anaerobic + MBR aerobic" treatment process[71]. - The company has established an EHS department and implemented various environmental management systems, including ISO14001 and ISO50001, to enhance pollution control and resource utilization[84]. - The company reported no exceedance of pollutant discharge standards in its operations[67]. Shareholder Information - The total number of ordinary shareholders reached 59,570 by the end of the reporting period[95]. - The top ten shareholders hold a total of 189,552,579 shares, representing 16.83% of the total shares outstanding[97]. - The report indicates that 90,000 shares from the equity incentive plan will become tradable on November 30, 2021, for shareholder Li Rong[100]. - The company has implemented an equity incentive plan that includes various shareholders with specific trading restrictions and release dates[100]. Risks and Challenges - The company faced risks including market competition, product development uncertainties, and potential regulatory changes impacting the veterinary vaccine sector[54]. - The company has outlined potential risks in the "Management Discussion and Analysis" section of the report[7].

证券代码：600201 证券简称：生物股份 公告编号：临2021-040 金宇生物技术股份有限公司 关于参加 2021 年投资者网上集体接待日活动的公告 | --- | |------------------------------------------------------------------------------| | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 为便于广大投资者更深入全面地了解公司治理、发展战略、经营状况及可持 | | 续发展等投资者所关心的问题，金宇生物技术股份有限公司（以下简称"公司"） | | 将于 2021 年 8 月 4 日（星期三）下午 15:00-17:00 参加 2021 | | 公司投资者网上集体接待日活动，现将有关事项公告如下: | | 本次年度集体接待日活动将在深圳市全景网络有限公司提供的网上平台采用 | | 网络远程的方式举行，投资者可以登录"全景路演天下"（ | | 参与本次互动交流。 | | 出席本次年度网上集体接待日活动的人员有：公 ...

Financial Performance - In 2020, the company's operating income reached ¥1,581,905,632.48, representing a 40.39% increase compared to ¥1,126,782,253.35 in 2019[21] - The net profit attributable to shareholders was ¥406,195,463.57, an increase of 83.76% from ¥221,041,634.94 in the previous year[21] - The cash flow from operating activities amounted to ¥699,612,782.08, reflecting a 72.64% increase from ¥405,242,914.07 in 2019[21] - The total assets of the company at the end of 2020 were ¥6,278,282,683.24, a 12.40% increase from ¥5,585,879,172.02 in 2019[22] - The net assets attributable to shareholders increased by 7.20% to ¥4,981,663,905.19 from ¥4,647,275,880.19 in 2019[22] - The basic earnings per share rose to ¥0.36, an 80.00% increase compared to ¥0.20 in 2019[23] - The weighted average return on equity increased to 8.37%, up by 3.88 percentage points from 4.49% in the previous year[23] Revenue and Profit Trends - Total revenue for the first quarter was ¥366,175,089.52, with a net profit attributable to shareholders of ¥150,513,913.05[25] - In the second quarter, total revenue decreased to ¥258,180,404.26, and net profit attributable to shareholders dropped to ¥31,931,767.81[25] - The third quarter saw a revenue increase to ¥483,387,661.41, with net profit attributable to shareholders at ¥113,287,251.42[25] - For the fourth quarter, total revenue was ¥474,162,477.29, and net profit attributable to shareholders was ¥110,462,531.29[25] Research and Development - The company has established multiple research and development platforms, including pathogen diagnosis and gene engineering expression platforms, to enhance vaccine development capabilities[32] - R&D investment over the past five years shows a significant increase, with 2020 investment at ¥2.07 billion, accounting for 13.09% of revenue, compared to ¥0.92 billion and 6.04% in 2016[38] - The company is the first in China to adopt suspension culture and purification technology for foot-and-mouth disease vaccine production, setting industry standards for antigen content and detection[38] - The company has developed multiple R&D platforms, including pathogen diagnosis and gene engineering, to enhance its vaccine development capabilities[38] - The company is actively engaged in the research and development of vaccines for foot-and-mouth disease, African swine fever, and brucellosis, being the first in China to conduct related experimental activities[79] Market and Sales Strategy - The sales model includes direct sales to large clients, a dealer network, and government tender procurement, with a focus on providing tailored disease prevention solutions[34] - The government procurement of vaccines is expected to cease for large-scale farms by the end of 2022, transitioning to a market-oriented sales model by 2025[35] - The company is actively expanding its international business, with significant progress in vaccine export registrations in countries like Pakistan and Vietnam[50] - The company’s main business revenue from biopharmaceuticals accounted for 95.93% of total revenue, with domestic revenue contributing 99.08% of total revenue[56] Corporate Governance and Shareholder Relations - The company has a policy to distribute at least 30% of the average distributable profit over the last three years in cash dividends, provided that the company is profitable and cash flow is sufficient[114] - The company’s cash dividend distribution policy emphasizes reasonable returns to investors while ensuring long-term development[114] - The company’s board of directors must approve any adjustments to the profit distribution policy, ensuring protection of shareholder rights[117] - The company held 2 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[191] Environmental Responsibility - The company generated 127.15 tons of hazardous waste from animal carcasses in 2020, which was disposed of by qualified entities[146] - The company reported a total wastewater discharge of 1.92 tons with a chemical oxygen demand of 36.89 mg/L, compliant with pollution discharge standards[144] - The wastewater treatment plant of Jinyu Baoling Bio-Pharmaceutical Co., Ltd. has a design capacity of 1000 tons per day and has been operational since 2005, with upgrades including COD online monitoring equipment in 2017 and ammonia nitrogen monitoring in 2018[148] - The company has established an annual self-monitoring plan for environmental compliance, with quarterly monitoring of wastewater, waste gas, and noise conducted by a third-party testing agency[152] Employee and Management Structure - The company employed a total of 1,444 staff, with 1,402 in major subsidiaries and 42 in the parent company[186] - The company has implemented a diversified compensation structure to support strategic goals, focusing on performance, compensation, and incentives[187] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period was 8.2103 million yuan[183] - The company has undergone changes in senior management, with new appointments for vice presidents and financial directors[184] Risk Management - The company faces risks related to the resurgence of African swine fever, which may impact vaccine demand due to varying recovery capabilities in the livestock sector[109] - The company recognizes the potential for product development risks due to long R&D cycles and strict approval processes for veterinary vaccines[111] - The company is exposed to market competition risks as the industry undergoes upgrades driven by regulatory changes and market demands[111]

Financial Performance - Net profit attributable to shareholders increased by 40.41% to CNY 211,332,445.68 year-on-year[11] - Operating revenue rose by 41.85% to CNY 519,424,062.86 compared to the same period last year[11] - Basic earnings per share increased by 46.15% to CNY 0.19 compared to the same period last year[11] - Total profit increased by 7,007,000 yuan, a growth of 38.50%, attributed to the rise in operating income[22] - The company's net profit for Q1 2021 was CNY 217,204,002.03, an increase of 37% compared to CNY 158,601,855.20 in Q1 2020[76] - The total comprehensive income for Q1 2021 was CNY 217,243,898.23, compared to CNY 158,651,560.98 in Q1 2020[78] Revenue and Costs - Total operating revenue for Q1 2021 reached RMB 519,424,062.86, a significant increase of 41.8% compared to RMB 366,175,089.52 in Q1 2020[72] - Total operating costs for Q1 2021 were RMB 272,001,358.64, up 48.3% from RMB 183,471,337.15 in Q1 2020[72] - Cash received from sales of goods and services increased by 10,414,000 yuan, up 47.48%, due to higher market-oriented vaccine sales[24] - Cash paid for purchasing goods and services increased by 6,811,000 yuan, a rise of 87.62%, reflecting higher raw material expenditures[24] Assets and Liabilities - Total assets increased by 3.16% to CNY 6,476,415,520.78 compared to the end of the previous year[11] - Total liabilities as of March 31, 2021, were RMB 309,724,888.39, a decrease from RMB 315,107,889.15 at the end of 2020[70] - The total equity attributable to shareholders increased to RMB 5,200,810,998.43 as of March 31, 2021, from RMB 4,981,663,905.19 at the end of 2020[55] Cash Flow - Net cash flow from operating activities decreased by 45.71% to CNY 27,069,382.49 compared to the previous year[11] - Cash inflow from operating activities totaled ¥360,859,864.96, an increase from ¥262,252,461.54 in the previous period, representing a growth of approximately 37.6%[86] - Cash outflow from operating activities was ¥333,790,482.47, compared to ¥212,393,144.93 previously, indicating a rise of about 57.1%[86] - Cash and cash equivalents at the end of the period stood at ¥1,236,675,331.77, a decrease from ¥1,273,110,964.79[88] Shareholder Information - The total number of shareholders reached 55,256 by the end of the reporting period[17] - The largest shareholder, Hong Kong Central Clearing Limited, holds 18.20% of the shares[17] Research and Development - Research and development expenses for Q1 2021 were RMB 29,028,789.46, up from RMB 22,536,657.41 in Q1 2020, indicating a focus on innovation[72] Future Plans - The company plans to continue expanding its market presence and invest in new product development[11] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[72]

Financial Performance - Operating income rose by 30.65% to CNY 1,107,743,155.19 for the first nine months of the year[17] - Net profit attributable to shareholders increased by 19.03% to CNY 295,732,932.28 year-on-year[17] - Total profit increased by RMB 83.39 million, up 31.30%, attributed to the recovery in the pig farming industry and the promotion of a combination immunization marketing plan[30] - Total operating revenue for Q3 2020 reached ¥483.39 million, a 43.6% increase from ¥336.61 million in Q3 2019[54] - Net profit attributable to shareholders for Q3 2020 was ¥113.29 million, compared to ¥78.46 million in Q3 2019, reflecting a 44.4% increase[61] - The total comprehensive income for the first three quarters of 2020 was ¥120,373,646.13, compared to ¥85,852,201.51 in the same period of 2019, representing an increase of about 40.2%[63] Assets and Liabilities - Total assets increased by 9.77% to CNY 6,131,452,234.03 compared to the end of the previous year[17] - Total liabilities reached $1.03 billion, up from $716.78 million, which is an increase of approximately 43.3%[44] - Shareholders' equity rose to $5.10 billion, compared to $4.87 billion, reflecting an increase of about 4.5%[44] - The company reported a total of $1.51 billion in current assets, slightly down from $1.53 billion, a decrease of about 0.5%[49] - The company’s total liabilities and shareholders' equity reached ¥4.38 billion, compared to ¥4.36 billion in the previous quarter[54] Cash Flow - Net cash flow from operating activities surged by 222.10% to CNY 403,880,298.08 for the first nine months[17] - Cash received from operating activities increased by RMB 149.83 million, a rise of 193.03%, mainly due to government subsidies received[31] - The net cash flow from operating activities was CNY 403,880,298.08, a significant increase from CNY 125,391,321.62 in the previous period, reflecting a strong operational performance[72] - Total cash inflow from investment activities amounted to CNY 539,714,796.79, down from CNY 1,528,665,904.04, indicating a decrease in investment returns[72] - Cash outflow from financing activities totaled CNY 106,731,676.95, a decrease from CNY 767,398,631.26, suggesting reduced financing costs[74] Shareholder Information - The total number of shareholders reached 36,158 by the end of the reporting period[21] - The largest shareholder, Hong Kong Central Clearing Limited, holds 16.09% of shares[21] Research and Development - Research and development expenses increased by RMB 24.75 million, a rise of 41.10%, due to increased experimental materials and operational costs for the ABSL-3 laboratory[30] - Research and development expenses for Q3 2020 amounted to ¥33.95 million, a significant increase of 78.5% from ¥19.04 million in Q3 2019[54] Government Subsidies - The company received government subsidies amounting to CNY 8,140,827.83 for the first nine months[20] Inventory and Receivables - Accounts receivable increased by RMB 208.38 million, a rise of 36.16%, mainly due to increased sales revenue from government procurement of vaccines for foot-and-mouth disease and highly pathogenic avian influenza[24] - Other receivables increased by RMB 21.31 million, up 49.89%, primarily due to increased payments and deposits in the biopharmaceutical sector[24] Changes in Expenses - Cash paid for dividends and interest decreased by RMB 329.98 million, down 83.20%, due to a reduction in cash dividends distributed compared to the previous year[32] - The company’s sales expenses for Q3 2020 were ¥89.68 million, an increase of 97.1% from ¥45.43 million in Q3 2019[54] - The company’s management expenses for Q3 2020 were ¥30.45 million, slightly up from ¥28.52 million in Q3 2019[54]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 624,355,493.78, representing a 22.13% increase compared to CNY 511,239,851.67 in the same period last year [20] - The net profit attributable to shareholders for the first half of 2020 was CNY 182,445,680.86, which is a 7.33% increase from CNY 169,982,656.90 in the previous year [20] - The net cash flow from operating activities reached CNY 106,483,123.49, showing a significant increase of 243.87% compared to CNY 30,966,054.13 in the same period last year [20] - Basic earnings per share for the first half of 2020 were CNY 0.16, a 6.67% increase from CNY 0.15 in the same period last year [21] - The company reported a net profit excluding non-recurring gains and losses of CNY 180,151,927.28, which is an 8.63% increase from CNY 165,836,302.83 in the same period last year [20] - The company reported a significant decrease in long-term borrowings by 82.89%, reducing it to ¥2.58 million due to reclassification of debts [39] - The company reported a gross profit margin of approximately 36.5% for the first half of 2020, compared to 36.0% in the previous year [93] - The company reported a total of 1,126,240,241 shares issued as of June 30, 2020, with a registered capital of CNY 1,126,240,241 [128] Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,803,489,770.66, up 3.90% from CNY 5,585,879,172.02 at the end of the previous year [20] - The net assets attributable to shareholders increased to CNY 4,752,720,854.24, reflecting a 2.27% growth from CNY 4,647,275,880.19 at the end of the previous year [20] - Total current assets increased to ¥2,797,574,986.20 as of June 30, 2020, up from ¥2,693,546,671.57 at the end of 2019, representing a growth of approximately 3.87% [81] - Total liabilities increased to ¥821,182,753.66 from ¥716,783,253.17, representing a rise of about 14.6% [86] - The total owner's equity at the end of the reporting period is CNY 4,664,053,265.97, a decrease of CNY 664,123,893.70 compared to the previous period [125] Research and Development - The company obtained 2 invention patents and 1 utility model patent during the reporting period, enhancing its R&D capabilities [36] - The company launched a new vaccine combination immunization scheme and a needle-free vaccination method, effectively addressing disease prevention challenges in the industry [36] - The company has established three national-level laboratories, which significantly improve the efficiency of research and development [29] - The company’s R&D expenses rose by 23.89% to approximately ¥51.01 million, reflecting increased investment in its ABSL-3 laboratory and related materials [36] Market Position and Strategy - The company has over 100 types of animal vaccines across four major series: pigs, poultry, ruminants, and pets, maintaining a leading position in technology and product quality domestically [27] - The company operates under a centralized procurement model, ensuring stable supply while minimizing procurement risks and costs [27] - The sales model includes direct sales to large clients, a distributor network, and government tender procurement, adapting to the fragmented nature of domestic farming [27] - The company is the first in China to conduct simultaneous research on foot-and-mouth disease and African swine fever vaccines, enhancing its core competitiveness in the animal vaccine industry [29] Environmental and Social Responsibility - The company actively donated anti-epidemic materials to support COVID-19 response efforts while fulfilling its corporate social responsibilities [36] - The company has implemented an annual self-monitoring plan for environmental protection, with real-time data uploaded to environmental authorities [67] - The company produced 51.66 tons of hazardous medical waste and 0.23 tons of waste oil, all of which were disposed of by qualified units [61] Shareholder Information - The total number of common stock shareholders reached 31,772 by the end of the reporting period [71] - The top ten shareholders hold a total of 419,000,000 shares, accounting for approximately 36.67% of the total shares [71] - Hong Kong Central Clearing Limited is the largest shareholder with 219,192,724 shares, representing 19.46% of the total [71] Risks and Challenges - The company faces risks including epidemic outbreaks, market competition, product development, biological safety, product quality, and policy changes [43][45] - There are no significant risks related to non-operating fund occupation by controlling shareholders or their related parties [8] Accounting and Financial Reporting - The financial statements are prepared based on the going concern principle, ensuring the company's ability to continue operations [133] - The accounting policies are aligned with the enterprise accounting standards, ensuring compliance and transparency in financial reporting [136] - The company recognizes the assets and liabilities of the acquired entity at their book value on the consolidation date, with adjustments made for differences in accounting policies [142]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 624,355,493.78, representing a 22.13% increase compared to CNY 511,239,851.67 in the same period last year [20] - The net profit attributable to shareholders for the first half of 2020 was CNY 182,445,680.86, which is a 7.33% increase from CNY 169,982,656.90 in the previous year [20] - The net cash flow from operating activities reached CNY 106,483,123.49, marking a significant increase of 243.87% compared to CNY 30,966,054.13 in the same period last year [20] - The basic earnings per share for the first half of 2020 were CNY 0.16, a 6.67% increase from CNY 0.15 in the same period last year [21] - The weighted average return on net assets increased to 3.85%, up 0.48 percentage points from 3.37% in the previous year [21] - The company reported a non-recurring gain of RMB 2,293,753.58, primarily from government subsidies related to normal business operations [24] - The company reported a significant increase in short-term borrowings, which rose to ¥629,384,243.06 from ¥548,004,329.16, reflecting an increase of about 14.77% [84] - The company reported a total comprehensive income of CNY 202,883,165.12 for the first half of 2020, compared to CNY 724,130,740.73 in the same period of 2019, showing a decline of approximately 72% [101] Assets and Liabilities - The total assets of the company at the end of the reporting period were CNY 5,803,489,770.66, up 3.90% from CNY 5,585,879,172.02 at the end of the previous year [20] - The net assets attributable to shareholders increased to CNY 4,752,720,854.24, reflecting a 2.27% growth from CNY 4,647,275,880.19 at the end of the previous year [20] - Total current assets increased to ¥2,797,574,986.20 as of June 30, 2020, up from ¥2,693,546,671.57 at the end of 2019, representing a growth of approximately 3.87% [81] - Total liabilities amounted to ¥821,182,753.66, up from ¥716,783,253.17, representing an increase of approximately 14.6% [86] - The company's total equity reached ¥4,982,307,017.00, compared to ¥4,869,095,918.85 at the end of 2019, showing an increase of about 2.32% [86] Research and Development - The company obtained 2 invention patents and 1 utility model patent during the reporting period, enhancing its R&D capabilities [36] - The company’s R&D expenses rose by 23.89% to approximately ¥51.01 million, reflecting increased laboratory material costs [36] - The company launched a new vaccine combination immunization scheme, effectively addressing epidemic prevention challenges in the industry [36] - The company specializes in the research, production, and sales of over 100 types of animal vaccines, covering pigs, poultry, ruminants, and pets [27] - The company has established three national-level laboratory platforms to enhance its research capabilities in animal vaccines [27] Market Position and Strategy - The company is the first in China to develop both foot-and-mouth disease and African swine fever vaccines, enhancing its competitive edge in the animal vaccine sector [29] - The company has achieved a leading market share in the domestic animal vaccine industry, particularly in foot-and-mouth disease vaccines [31] - The sales model includes direct sales to large clients, a distributor network, and government tender procurement, adapting to the fragmented nature of the domestic farming industry [27] - The company aims to internationalize its operations and enhance brand value through customized disease prevention solutions [31] Environmental and Social Responsibility - The company actively donated anti-epidemic materials, including nucleic acid test kits and protective clothing, to support COVID-19 response efforts [36] - The company has implemented online monitoring systems for COD and ammonia nitrogen, which passed inspections in 2018 [62] - The company has established an environmental risk emergency plan, approved by experts and filed with environmental authorities [66] Shareholder Information - The total number of common stock shareholders reached 31,772 by the end of the reporting period [71] - The top ten shareholders hold a total of 419,000,000 shares, accounting for 36.73% of the total shares [71] - Hong Kong Central Clearing Limited is the largest shareholder with 219,192,724 shares, representing 19.46% of the total [71] Accounting and Compliance - The company continues to employ Deloitte Touche Tohmatsu as its auditor for the 2020 fiscal year [48] - The company has not proposed any profit distribution or capital reserve increase plans for the first half of 2020 [48] - The company reported no changes in accounting policies or estimates during the reporting period [69] - There were no significant accounting errors that required restatement in the reporting period [69] Risks and Challenges - The company faces risks including epidemic outbreaks, market competition, product development uncertainties, and regulatory changes [43] - The company has detailed potential risks in the report, advising investors to pay attention to investment risks [8]

证券代码：600201 证券简称：生物股份 公告编号：临2020-038 金宇生物技术股份有限公司关于 参加 2020 年投资者网上集体接待日活动的公告 | --- | |-------------------------------------------------------------------------------| | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 为便于广大投资者更深入全面地了解公司治理、发展战略、经营状况及可持 | | 续发展等投资者所关心的问题，金宇生物技术股份有限公司（以下简称"公司"） | | 将于 2020 年 6 月 18 日（星期四）下午 14:30-16:30 参加 2020 | | 资者网上集体接待日活动，现将有关事项公告如下 : | | 本次年度集体接待日活动将在深圳市全景网络有限公司提供的网上平台采用 | | 网络远程的方式举行，投资者可以登录"内蒙古辖区上市公司投资者关系互动平 | | 台"（ http://rs.p5w.net ）参与本 ...